<unk>  is a liposomal combination of<unk> , an anthracycline topoisomerase inhibitor, and<unk> , a nucleoside metabolic inhibitor that is FDA approved for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include hemorrhagic events, febrile neutropenia, rash, edema, nausea, mucositis, diarrhea, constipation, musculoskeletal pain, fatigue, abdominal pain, dyspnea, headache, cough, decreased appetite, arrhythmia, pneumonia, bacteremia, chills, sleep disorders, and vomiting.
Daunorubicin / cytarabine
Dihydroergocristine
Epirubicin hydrochloride
Vincristine sulfate
Taxane
Mafosfamide
Epirubicin
Ifosfamide